<PAGE>
--------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------------------------------
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
Crescendo Pharmaceuticals Corporation
-------------------------------------
(Name of Issuer)
Class A Common Stock, Par Value $0.01
-------------------------------------
(Title of Class of Securities)
225637 10 7
-----------
CUSIP Number
Peter D. Staple, Esq.
ALZA Corporation
1900 Charleston Road, P.O. Box 7210
Mountain View, California 94039-7210
(650) 564-5000
With a copy to:
Alan Jacobs, Esq.
Heller Ehrman White & McAuliffe LLP
4250 Executive Square, 7th Floor
La Jolla, California 92037-9103
(858) 450-8400
-----------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
November 13, 2000
------------------------------------------------------------
(Date of Event which requires Filing of this statement)
---------------------
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
If the filing person has previously filed a statement on Schedule 13G to
Page 1
<PAGE>
report the acquisition which is the subject of this Schedule 13D, and is filing
this schedule because of Rule 13d-1(b)(3) or (4), check the following box: [ ].
Note. Schedules filed in paper format shall include a signed original and
five copies of the schedule, including all exhibits. See Rule 13d-7 for other
parties to whom copies are to be sent.
Page 2 of 13 Pages
CUSIP No. 225637 10 7 13D Page 3 of 13 Pages
---------------------------- -----------------------------
1 Names of reporting persons
I.R.S. identification No.. of above persons (entities only)
ALZA Corporation
I.R.S. Identification No. 77-0142070
--------------------------------------------------------------------------------
2 Check the appropriate box if a member of a group (a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC use only
-------------------------------------------------------------------------------
4 Source of funds*
00
-------------------------------------------------------------------------------
5 Check box if disclosure of legal proceedings is required [ ]
Pursuant to item 2(d) or 2(e)
-------------------------------------------------------------------------------
6 Citizenship or place of organization
Delaware
-------------------------------------------------------------------------------
NUMBER OF 7 Sole voting power
SHARES 4,933,509 Shares of Class A Common Stock
--------------------------------------------------------
BENEFICIALLY 8 Shared voting power
OWNED BY None
--------------------------------------------------------
EACH 9 Sole dispositive power
REPORTING 4,933,509 Shares of Class A Common Stock
--------------------------------------------------------
PERSON WITH 10 Shared dispositive power
None
-----------------------------------------------------------------------------
11 Aggregate amount beneficially owned by each reporting person
4,933,509 Shares of Class A Common Stock and 1000 Shares of Class B Common
Stock.
-------------------------------------------------------------------------------
12 Check box if the aggregate amount in row (11) excludes certain shares
-------------------------------------------------------------------------------
13 Percent of class represented by amount in row (11)
100%
-------------------------------------------------------------------------------
14 Type of reporting person*
CO
--------------------------------------------------------------------------------
Page 2
<PAGE>
*SEE INSTRUCTIONS BEFORE FILLING OUT!
Item 1. Security and Issuer.
-------------------
This statement constitutes Amendment No. 2 to the Statement on Schedule
13D, dated September 18, 1997, relating to shares of Class A Common Stock, par
value $0.01 per share (the "Class A Shares") of Crescendo Pharmaceuticals
Corporation, a Delaware corporation ("Crescendo"). The principal executive
office of Crescendo is located at 2000 Charleston Road, Suite 300, Mountain
View, CA 94043. Unless otherwise indicated, all capitalized terms not otherwise
defined herein shall have the same meanings as those set forth in the initial
Schedule 13D.
The reporting person, ALZA Corporation, a Delaware corporation ("ALZA"), is
filing this Amendment No. 2 on Schedule 13D because, on November 13, 2000, it
closed the exercise of its option to purchase all of the issued and outstanding
Class A Shares of Crescendo. As a consequence, ALZA now owns all issued and
outstanding stock of Crescendo and Crescendo is a wholly owned subsidiary of
ALZA.
Page 3
<PAGE>
Item 5. Interest in Securities of the Issuer.
-------------------------------------
As of November 13, 2000, ALZA owns 4,933,509 Class A Shares of Crescendo. ALZA
owns 100% of the issued and outstanding stock of Crescendo.
Item 7. Exhibits.
--------
None
Page 4
<PAGE>
SIGNATURE
After due inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
November 13, 2000
ALZA CORPORATION
BY: /s/ Peter D. Staple
__________________________
Peter D. Staple,
Executive Vice President,
Chief Administrative Officer
and General Counsel
Page 5
